This Article Full Text Full Text (PDF) Data Supplement Data Supplement All Versions of this Article: 24/4/756    most recent 01.ATV.0000119353.03690.22v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Recalde, D. Articles by Scott-Algara, D. Search for Related Content PubMed PubMed Citation Articles by Recalde, D. Articles by Scott-Algara, D. Related Collections Pathophysiology

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:756.)
© 2004 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Human Apolipoprotein A-IV Reduces Secretion of Proinflammatory Cytokines and Atherosclerotic Effects of a Chronic Infection Mimicked by Lipopolysaccharide

Delia Recalde; Maria A. Ostos; Edgar Badell; Angel-Luis Garcia-Otin; Josette Pidoux; Graciela Castro; Mario M. Zakin; Daniel Scott-Algara

From Unité d’Expression des Gènes Eucaryotes (D.R., M.A.O., A.-L.G.-O., J.P., M.M.Z.), Institut Pasteur, Paris, France; Unité de Génétique Mycobactérienne (E.B.), Institut Pasteur, Paris, France; U545 Inserm (G.C.), Institut Pasteur and Faculté de Pharmacie, Université Lille II, Lille, France; and Unité d’Immuno-Hématologie et d’Immunopathologie (D.S.-A.), Institut Pasteur, Paris, France.

Correspondence to D. Scott-Algara, Institut Pasteur, 28, rue du Docteur Roux, 75724 Paris Cedex 15, France. E-mail scott{at}pasteur.fr

Objective— Expression of human apolipoprotein (h-apo) A-IV in apoE-deficient (apoE₀) mice (h-apoA-IV/E₀) reduces susceptibility to atherosclerosis. Chronic infection mimicked by exposure to lipopolysaccharide (LPS) increases the size of atherosclerosis lesions in apoE₀ mice. Thus, we used h-apoA-IV/E₀ mice to determine whether h-apoA-IV plays a protective role after LPS administration.

Methods and Results— We injected apoE₀, h-apoA-IV/E₀, and C57Bl/6 (wild-type) mice intraperitoneally with either LPS or phosphate-buffered saline (PBS) every week for 10 weeks. Atherosclerotic lesions were significantly smaller in h-apoA-IV/E₀ mice treated with LPS than in their apoE₀ counterparts. The titers of IgG2a and IgG2b autoantibodies to oxidized low-density lipoprotein (LDL) were higher in the LPS-group of h-apoA-IV/E₀ mice than in apoE₀ mice, suggesting that the Th1 response is stronger in the presence of h-apoA-IV. Lymphocytes from the blood, liver, spleen, and thymus of h-apoA-IV/E₀ mice treated with LPS produced less IL-4, INF-, and TNF- proinflammatory cytokines than their apoE₀ counterparts. Furthermore, we demonstrated that recombinant h-apoA-IV blocks the LPS-induced stimulation of monocytes.

Conclusions— The expression of h-apoA-IV in apoE₀ mice reduces the susceptibility to atherogenesis and decreases the secretion of proinflammatory cytokines after LPS administration.

Key Words: apolipoproteins • atherosclerosis • inflammation • transgenic mice • lipopolysaccharide

This article has been cited by other articles:

				P. A. Thompson, J. F.P. Berbee, P. C.N. Rensen, and R. L. Kitchens Apolipoprotein A-II augments monocyte responses to LPS by suppressing the inhibitory activity of LPS-binding protein Innate Immunity, December 1, 2008; 14(6): 365 - 374. [Abstract] [PDF]

				J. M. Gitlin and C. D. Loftin Cyclooxygenase-2 inhibition increases lipopolysaccharide-induced atherosclerosis in mice Cardiovasc Res, November 16, 2008; (2008) cvn286v2. [Abstract] [Full Text] [PDF]

				M. R. Tubb, R. A. G. D. Silva, J. Fang, P. Tso, and W. S. Davidson A Three-dimensional Homology Model of Lipid-free Apolipoprotein A-IV Using Cross-linking and Mass Spectrometry J. Biol. Chem., June 20, 2008; 283(25): 17314 - 17323. [Abstract] [Full Text] [PDF]

				M. Westerterp, J. F.P. Berbee, N. M.M. Pires, G. J.D. van Mierlo, R. Kleemann, J. A. Romijn, L. M. Havekes, and P. C.N. Rensen Apolipoprotein C-I Is Crucially Involved in Lipopolysaccharide-Induced Atherosclerosis Development in Apolipoprotein E Knockout Mice Circulation, November 6, 2007; 116(19): 2173 - 2181. [Abstract] [Full Text] [PDF]

				P. Thaveeratitham, W. Plengpanich, W. Naen-Udorn, S. Patumraj, and W. Khovidhunkit Effects of human apolipoprotein A-I on endotoxin-induced leukocyte adhesion on endothelial cells in vivo and on the growth of Escherichia coli in vitro Innate Immunity, February 1, 2007; 13(1): 58 - 64. [Abstract] [PDF]

				A. Kontush and M. J. Chapman Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374. [Abstract] [Full Text] [PDF]

				R. Y.L. Zee, N. R. Cook, S. Cheng, H. A. Erlich, K. Lindpaintner, and P. M Ridker Polymorphism in the {beta}2-Adrenergic Receptor and Lipoprotein Lipase Genes as Risk Determinants for Idiopathic Venous Thromboembolism: A Multilocus, Population-Based, Prospective Genetic Analysis Circulation, May 9, 2006; 113(18): 2193 - 2200. [Abstract] [Full Text] [PDF]

				J. F.P. Berbee, L. M. Havekes, and P. C.N. Rensen Apolipoproteins modulate the inflammatory response to lipopolysaccharide Innate Immunity, April 1, 2005; 11(2): 97 - 103. [Abstract] [PDF]

				W.-m. R. Wong, J. W. Stephens, J. Acharya, S. J. Hurel, S. E. Humphries, and P. J. Talmud The APOA4 T347S variant is associated with reduced plasma TAOS in subjects with diabetes mellitus and cardiovascular disease J. Lipid Res., August 1, 2004; 45(8): 1565 - 1571. [Abstract] [Full Text] [PDF]

				W. Khovidhunkit, M.-S. Kim, R. A. Memon, J. K. Shigenaga, A. H. Moser, K. R. Feingold, and C. Grunfeld Thematic review series: The Pathogenesis of Atherosclerosis. Effects of infection and inflammation on lipid and lipoprotein metabolism mechanisms and consequences to the host J. Lipid Res., July 1, 2004; 45(7): 1169 - 1196. [Abstract] [Full Text] [PDF]